# Atlanthene Pharma Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/atlanthene-pharma-co

- Industry: Biotechnology
- Headquarters: Osaka-shi, Japan
- Website: www.atransen.com/
- Latest round: Series A (May 30, 2025)
- Investors on record: 2

## About

Founded in 2022 and headquartered in Osaka-shi, Japan, Atransen Pharma Ltd. focuses on the research and development of cancer therapies, particularly targeting LAT1 inhibitors. The company has completed one deal as of May 30, 2025. Details regarding the founder's history or previous ventures are not provided. Atransen Pharma Ltd. specializes in developing innovative cancer therapies, focusing on treatments that target amino acid transporters and particularly LAT1 inhibitors. These inhibitors are designed to inhibit the uptake of essential amino acids critical for tumor growth, thus suppressing cancer cell proliferation. The company aims to provide treatment options with fewer side effects than traditional therapies, catering to healthcare providers, hospitals, and oncology clinics across Japan, the United States, and Europe. Atransen Pharma Ltd. generates revenue primarily through partnerships and collaborations with healthcare institutions and pharmaceutical companies. Their business model involves B2B transactions, where LAT1 inhibitor products are supplied to hospitals and clinics for cancer treatment. Revenue is structured around contractual agreements, which may include licensing fees, milestone payments, and royalties based on product sales. These strategic partnerships are integral to the company's financial growth as it continues to advance its clinical pipeline. In May 2025, Atransen Pharma Ltd. raised an undisclosed amount in SERIES A funding from new investors JAFCO Group and Osaka University Venture Capital, as part of a larger JPY 1.13 billion equity and grant funding round. This funding will be utilized to prepare for clinical trials of its cancer treatment medicine, hire new employees, and further develop its business operations. The company aims to introduce new products into the market and expand its footprint into additional regions, including North America and Europe, by targeting these markets for its innovative cancer therapies.

## Funding rounds

- Series A, May 30, 2025 — JAFCO Group, Osaka University Venture Capital

## Investors

- JAFCO Group (https://capitalatlas.ai/funds/jafco-group) — Series A
- Osaka University Venture Capital (https://capitalatlas.ai/funds/osaka-university-venture-capital) — Series A